Chapter from the book *Advances in Endoscopic Surgery*
Downloaded from: http://www.intechopen.com/books/advances-in-endoscopic-surgery
Endoscopic Ultrasound for Solid and Cystic Neoplasms of the Pancreas

Karim M. Eltawil¹ and Michele Molinari²

¹Dalhousie University, Department of Surgery, Queen Elizabeth II Health Sciences Centre, Rm 6-302 Victoria Building, Halifax, Nova Scotia
²Associate Professor of Surgery, Rm 6-302 Victoria Building, Halifax, Nova Scotia

1. Introduction

Endoscopic ultrasound (EUS) was introduced in clinical practice in 1980¹ and during the last few decades the quality of instrumentation has improved significantly. The first commercially available radial echoendoscope was introduced in Japan ² and then in Europe ³ in the mid to late 1980s. At that time, radial probes were used for fine needle aspiration (FNA). Only in the early 1990s EUS-FNA become technologically practical with the introduction of linear echoendoscopes that generated ultrasonic images parallel to the shaft of the instrument. With this modification, needles could be guided into areas of interest. Soon after this improvement, the first report of EUS-FNA of the pancreas was published ⁴ and numerous other publications have followed ⁵⁻⁸. Later on, mechanical probes have been replaced by electrical probes that allowed expansion of the diagnostic capacity of EUS. More recently, the addition of color Doppler ultrasonography, injection of contrasts for ultrasound and the application of elastography has further extended the clinical use of EUS for hepatobiliary and pancreatic diseases. The fact that EUS is able to provide direct visualization of the walls of the gastrointestinal tract and direct the placement of needles for cytology or histology specimens ⁹⁻¹⁰, makes this technique very useful for the diagnosis of benign and malignant diseases of these organs that are difficult to reach percutaneously. In recent years diagnostic modalities such as multidetector-multiphasic CT with pancreatic protocols, magnetic resonance imaging (MRI) and positron emission tomography (PET) scans have improved significantly the pre-operative tumor staging of pancreatic malignancies. Nevertheless, a significant proportion of patients will benefit from EUS-FNA for confirmation of pancreatic neoplasm and assessment of the planes along the vascular superior mesenteric trunk¹⁰.

2. Epidemiology of pancreatic neoplasms

Pancreatic adenocarcinoma is the fourth leading cause of cancer related mortality in the United States with estimated 42,500 new cases and 35,000 deaths from the disease each year ¹¹. In industrialized countries, the incidence of pancreatic adenocarcinoma (11 per 100,000 individuals) ranks second after colorectal cancer among all gastrointestinal malignancies¹². More than 80% of PCs are diagnosed in patients older than 60 and almost 50% have distant metastases at the time of presentation¹³,¹⁴. Men are more frequently affected than women.
(Relative Risk (RR) = 1.3) and individuals of African American descent in comparison to Caucasians (RR= 1.5). Analysis of overall survival shows that the prognosis of PC is still quite poor despite the fact that 1-year survival has increased from 15.2% (period between 1977-1981) to 21.6% (period between 1997-2001) and 5-year survival has increased from 3% (period between 1977-1986) to 5% (period between 1996-2004).

3. Classification of pancreatic neoplasms

The vast majority (90%) of pancreatic cancers (PC) are malignant tumors originating from pancreatic ductal cells. Anatomically, 78% of PCs are located in the head, and the remaining 22% are equally distributed in the body and in the tail. The most common

<table>
<thead>
<tr>
<th>EPITHELIAL TUMORS</th>
<th>NON-EPITHELIAL TUMORS</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Benign Pancreatic Tumors</strong></td>
<td><strong>Endocrine Tumors</strong></td>
</tr>
<tr>
<td>Serous Cystoadenoma</td>
<td>Insulinoma (Incidence: 70-80%)</td>
</tr>
<tr>
<td>Mucinous Cystoadenoma</td>
<td>Gastrinoma (Incidence: 20-25%)</td>
</tr>
<tr>
<td>Intraductal Papillary Mucinous Neoplasm (IPMN)</td>
<td>VIPoma (Incidence: 4%)</td>
</tr>
<tr>
<td>Mature Teratoma</td>
<td>Glucagonoma (Incidence: 4%)</td>
</tr>
<tr>
<td><strong>Borderline Pancreatic Tumors</strong></td>
<td>Somatostatinoma (Incidence: &lt;5%)</td>
</tr>
<tr>
<td>Mucinous Cystic Neoplasm with Moderate Dysplasia</td>
<td>Carcinoid (Incidence: &lt;1%)</td>
</tr>
<tr>
<td>Intraductal Papillary Mucinous Neoplasm with Moderate Dysplasia</td>
<td>ACTHoma (Incidence: &lt;1%)</td>
</tr>
<tr>
<td>Solid-pseudopapillary Neoplasm (SPPN)</td>
<td>GRFoma (Incidence: &lt;1%)</td>
</tr>
<tr>
<td><strong>Malignant</strong></td>
<td>PTH-like-oma (Incidence: &lt;1%)</td>
</tr>
<tr>
<td>Ductal Adenocarcinoma</td>
<td>Neurotensinoma (Incidence: &lt;1%)</td>
</tr>
<tr>
<td>Mucinous non-cystic carcinoma</td>
<td>Non-functional tumors (Incidence 30-50%)</td>
</tr>
<tr>
<td>Signet ring cell carcinoma</td>
<td><strong>Mesenchymal Neoplasms</strong></td>
</tr>
<tr>
<td>Undifferentiated (anaplastic) carcinoma</td>
<td>Leiomyoma</td>
</tr>
<tr>
<td>Undifferentiated carcinoma with osteoclast-like giant cells</td>
<td>Lipoma</td>
</tr>
<tr>
<td>Mixed ductal-endocrine carcinoma</td>
<td>Neurofibroma - Ganglioneuromas</td>
</tr>
<tr>
<td>Serous Cystoadenocarcinoma</td>
<td>Hemangyoma - Lymphangioma</td>
</tr>
<tr>
<td>Mucinous Cystoadenocarcinoma</td>
<td>Granular Cell Tumors</td>
</tr>
<tr>
<td>Intraductal Papillary-Mucinous Carcinoma</td>
<td>Schwann Cell Tumors</td>
</tr>
<tr>
<td><strong>Others</strong></td>
<td>Gastrointestinal Stroma Tumors (GIST)</td>
</tr>
<tr>
<td>Acinar Cell Carcinoma</td>
<td>B-cell Lymphomas</td>
</tr>
<tr>
<td>Medullary Carcinoma</td>
<td><strong>Metastatic Tumors</strong></td>
</tr>
<tr>
<td>Acinar Cell Cystoadenocarcinoma</td>
<td>Renal Cell Carcinoma</td>
</tr>
<tr>
<td>Pancreatoblastoma</td>
<td>Melanoma</td>
</tr>
<tr>
<td>Solid-pseudopapillary Carcinoma</td>
<td>Breast Cancer</td>
</tr>
<tr>
<td><strong>Secondary Tumors</strong></td>
<td>Squamous Cell Carcinoma</td>
</tr>
<tr>
<td></td>
<td>Endometrioid Adenocarcinoma</td>
</tr>
<tr>
<td></td>
<td>Osteosarcoma</td>
</tr>
</tbody>
</table>

Table 1. Tumor Classification
clinical presentations are progressive weight loss and anorexia, mid abdominal pain and jaundice. Pancreatic neoplasms are classified in benign or malignant according to the cytological characteristics. These can be further divided into endocrine or exocrine tumors according to the function of their cells and into cystic or solid according to the macroscopic features of the lesion. Recent advances in surgical pathology techniques integrated with molecular biology have allowed advances in the modern classification of pancreatic neoplasms. A summary of the clinico-pathological features of the different categories of pancreatic lesions is shown in Table 1.

4. Conventional diagnostic modalities for pancreatic cancer

4.1 Abdominal ultrasound

Trans-abdominal ultrasound (US) is often used as a screening test. Its sensitivity ranges between 48% and 89% with accuracy between 46% and 64%. Small tumors measuring less than 1cm are detected by US in only 50% of cases while the sensitivity increases to 95.8% for tumors larger than 3 cm. US has a relatively low performance profile for staging of pancreatic tumors as its sensitivity for lymph nodes involvement ranges only between 8 to 57%. Color Doppler US has been used to assess possible involvement of the portal vein and superior mesenteric vessels with a sensitivity ranging between 50% and 94% specificity between 80% and 100% and accuracy between 81% and 95%.

4.2 Computed Tomography

On contrast CT, pancreatic adenocarcinoma appears as an ill-defined, hypo attenuating focal mass with dilatation of the upstream pancreatic and or biliary duct. The optimum visualization of the pancreas requires imaging acquisition obtained during both arterial and portal phases with sensitivity and specificity of 77% and 100% respectively for lesions less than 2 cm. In a multicentric trial, the diagnostic accuracy of contrast CT for resectability was 73% with 90% PPV for non resectability. With the advent of multi detector CT scanners (MDCT) the pancreas can be imaged at a very high spacial and temporal resolution. Recent studies have shown that NPV for respectability was 87% for MDCT compared to 79% for conventional helical CT and with accuracy between 85% and 95%.

4.3 Magnetic Resonance Imaging (MRI-MRCP)

In most institutions, MRI is performed when other imaging modalities provide insufficient data for the clinical staging of the tumor or when treatment planning can not be based on the images obtained by other techniques. Several studies have shown that MRI is superior to CT scan for the detection and staging of pancreatic adenocarcinoma (100% vs. 94% respectively). The use of MRI-MRCP for pancreatic malignancies is supported by a prospective analysis showing that MRI-MRCP was superior to CT in differentiating malignant from benign lesions and MRI-MRCP had better sensitivity (92% vs. 76%), specificity (85% vs. 69%), accuracy (90% vs. 75%), PPV (95% vs. 88%) and NPV (79% vs. 50%) compared to CT.

4.4 Positron Emission Tomography

18F-2fluoro-2-deoxy-D-glucose (FDG) accumulated by tumor cells provides PET the advantage of combining metabolic activity and imaging characteristics. Newly developed PET scanners can detect small PC up to 7mm in diameter and diagnose metastatic disease in
about 40% of cases\textsuperscript{38,39}. A Japanese study found that the overall sensitivity of PET-CT was superior to contrast CT (92\% vs. 88\%) and that PET was better at detecting bone metastases (100\% vs. 12\%). However, CT scan was superior for the evaluation of vascular invasion (100\% vs. 22\%), involvement of para-aortic regional lymph nodes (78\% vs. 57\%), identification of peritoneal dissemination (57\% vs. 42\%) and hepatic metastases (73\% vs. 52\%)\textsuperscript{40}.

4.5 Treatment of pancreatic neoplasms
Solid tumors of the pancreas are typically associated with malignancy, whereas cystic tumors more often tend to be benign\textsuperscript{41}. Due to the difficulties in differentiating benign from malignant lesions, resection is often indicated when patient’s conditions and tumor stage allows it\textsuperscript{42}. Surgical resection with negative margins is the only potential curative treatment for pancreatic malignancies but unfortunately, even when surgery is performed successfully, recurrent disease is frequent and long term survival is expected only for 5-15\% of patients\textsuperscript{47}. According to the United States Surveillance and Epidemiology End Results registries, the 5-year relative survival for the period between 1999 and 2006 was 22.5\% for localized and 1.9\% for metastatic tumors\textsuperscript{43}. The majority of tumors are diagnosed when locally advanced or with early metastases, and only 20\% are suitable for resection at the time of diagnosis. Despite the improvements in surgical techniques and advances in perioperative supportive care that have reduced the mortality rates to less than 5\% in high volume centers, pancreatic surgery remains challenging\textsuperscript{44-46}. Therefore, pre-operative accurate staging is fundamental in identifying patients who would benefit from surgery. EUS has been shown to play an important role in preoperative diagnosis and tumor staging as it provides high resolution images of the pancreas without interference of bowel gas\textsuperscript{47}.

4.6 EUS equipment and techniques
EUS is usually performed with patients positioned in the left decubitus and under conscious sedation. The transducer located in the tip of the oblique-viewing fiberscope is inserted as far as the second portion of the duodenum, and scanning is done with a de-areated water filled balloon applied to the tip of the echoendoscope. After examination of the pancreatic head, the echoendoscope is drawn backward to the stomach, and EUS of the body and tail of the pancreas is performed. The frequency usually used to assess the pancreas and surrounding organs during EUS ranges between 5 and 12 MHz\textsuperscript{48}. During the last decade, intraductal US (IDUS) has been possible by the introduction of miniprobe measuring 1.7-2.4 mm in outer diameter that can be advanced in the common bile and pancreatic ducts utilizing scanning frequencies ranging between 10-30MHz and obtaining a maximum tissue view penetration of approximately 2 cm\textsuperscript{1,48}. The miniprobe is initially introduced into the papilla of Vater and advanced into the pancreatic or bile duct beyond the area of interest and then it is slowly pulled back. The location of the miniprobe can be confirmed by using fluoroscopy as it is usually done during regular endoscopic retrograde cholangiopancreatography (ERCP). IDUS is able to visualize only limited parts of the pancreas and surrounding structure such as the splenic vessels, portal vein, superior mesenteric artery and vein and extrahepatic duct.

4.7 Indications for Endoscopic Ultrasound and Fine Needle Aspiration (EUS-FNA)
The most common indication for EUS-FNA of the pancreas is for evaluation of pancreatic masses with atypical characteristicics on cross sectional images or for optimal pre-operative
staging (Table 2). Differential diagnosis of pancreatic masses includes malignant and benign neoplasms, chronic pancreatitis, lymphoma and metastases. Approximately 90% of pancreatic neoplasms are adenocarcinomas, 5% are cystic lesions, and 2-5% are neuroendocrine tumors. Metastatic lesions to the pancreas, primarily from renal cancer, lung cancer, and lymphomas represent a small percentage. Because cystadenocarcinomas and neuroendocrine tumors have a significantly better prognoses than pancreatic adenocarcinoma, accurate cytologic preoperative identification can significantly alter the subsequent management of these patients. In general, EUS has been shown to be superior to CT, MRI, and ERCP in the diagnosis of pancreatic diseases as an imaging modality. The current sensitivity of EUS is in the range of 95-100%. During the last decades, the diagnostic advantages of EUS for pancreatic pathology have been challenged by the advances of other cross sectional modalities such as CT, MRI and PET scans. When combined with FNA capabilities, EUS has the advantage of being able to sample suspicious lesions. The one area where malignancies can be still easily missed by EUS, even with EUS-FNA, is in the setting of underlying chronic pancreatitis. No single or combination of imaging modalities has yet proven accurate in definitively determining when a patient with chronic pancreatitis has developed pancreatic cancer. The technique of EUS-guided FNA involves passing an 18 to 22 gauge metal needle through the biopsy port of a linear echoendoscope under real-time guidance into an endosonographically visualized pancreatic mass. The needle is then moved back and forth several times (5-10 passes) with varying degrees of negative pressure to collect cells or small tissue samples that are then deposited on cytology slides for immediate fixation and staining. EUS-FNA of primary pancreatic malignancies is able to provide a definitive diagnosis in 80-93% of cases. The ability to have a cytopathologist on site who can provide immediate feedback on the quality and adequacy of the specimens obtained by FNA is extremely important for the accurate diagnosis. Choosing what part of a pancreatic mass to aspirate is something of an art and comes with experience. The most difficult pancreatic masses to aspirate are the ones located near the uncinate process as it can be very hard to direct the needle to enter the lesion around the second and third portion of the duodenum. The best yield of diagnostic cells usually seems to come from 1 cm to 2 cm deep to the margin of the tumor. Color flow Doppler can be used prior to EUS-FNA to help avoid vessels overlying the proposed path of the aspiration needle such as are seen when there is underlying portal vein or splenic vein obstruction. Similarly to CT and ultrasound-guided FNA or biopsy, the overall complication rate secondary to EUS-FNA of the pancreas is about 1-2%. The major complications reported with EUS-FNA are bleeding, pancreatitis, and infection but mortality is very rare.

### Indications for EUS

<table>
<thead>
<tr>
<th>Indications for EUS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute onset of diabetes in elderly patients</td>
</tr>
<tr>
<td>Involuntary weight loss</td>
</tr>
<tr>
<td>Presence of epigastric or back pain</td>
</tr>
<tr>
<td>Acute or chronic pancreatitis</td>
</tr>
<tr>
<td>Suspected pancreatic cancer on other cross sectional imaging modalities</td>
</tr>
<tr>
<td>Family history of pancreatic cancer or presence of genetic predisposition to pancreatic cancer</td>
</tr>
</tbody>
</table>

Table 2. Common Indications for Endoscopic Ultrasound
and usually caused by uncontrollable hemorrhage that is more likely when the patient has portal hypertension. Pancreatitis after EUS-FNA is most likely to occur in patients already being evaluated for recurrent pancreatitis and when the FNA needle is passed through more than 2 cm to 3 cm of normal pancreas to obtain a specimen. Bacteremia following EUS-FNA for solid tumors is quite uncommon while EUS-FNA of cystic pancreatic lesions has a higher risk of infectious complications and broad-spectrum intravenous antibiotics are routinely recommended. The risk of cancer seeding by EUS-FNA appears to be significantly lower when compared to percutaneous FNA.

4.8 EUS-FNA for benign pancreatic lesions
Indications and impact of EUS-FNA for benign disease other than pancreatic cystic lesions is still in evolution as it appears to be safe but does not add significantly to the diagnostic accuracy of EUS or other cross sectional imaging tests.

4.9 Ultrasonographic characteristics
Pancreatic adenocarcinoma often appears as a mass with irregular echogenicity due to the irregularly arranged carcinomatous canaliculi or coagulative necrosis of the neoplastic cells superimposed on a hypoechoic background. Small pancreatic cancers instead, can often have homogeneous and hypoechoic echogenicity that can mimic benign diseases such as focal pancreatitis, pseudotumors or islet cell neoplasms that have clear margins, smooth contour and regular central echogenicity. When compared to CT scan and ERCP, EUS performs better for the detection of small pancreatic cancers (less than 2 cm in diameter) and it is currently indicated when patients are suspected to have early stage tumors or when undergoing screening for familial pancreatic cancer as it is the most sensitive diagnostic test for lesions measuring less than 1 cm in diameter.

5. Differential diagnosis of pancreatic lesions
Differentiation between pancreatic malignancies from inflammatory masses has been very challenging with the use of cross sectional imaging modalities such as US, CT scans, MRI and ERCP. EUS-FNA appears to be the best diagnostic strategy as it combines the ability of ultrasound imaging of the pancreatic lesions and the ability of obtaining samples for cytological or histological evaluation. Recent studies have reported that adequate specimen acquisition is possible in 97% of cases with accurate differential diagnosis in 87% of patients. Sensitivity, specificity, positive predictive value and negative predictive value for EUS-FNA were: 85%, 100%, 100% and 53% respectively (Table 3). One of the major pitfalls is over interpretation of a lesion as positive for malignancy as a result of contamination of dysplastic cells when the needle traverses an area of high-grade dysplasia of the gastrointestinal tract mucosa. It is equally important that benign mucosal glandular cells in the aspirate of the lymph node not be over interpreted as metastasis. Although EUS-FNA is a very useful diagnostic technique for the differential diagnosis of patients with pancreatic lesions, it has to be kept in mind that even if the results of the test are negative for malignancy, pancreatic cancer can not be completely excluded. Currently, EUS-FNA should be still used in conjunction with other imaging modalities and repeated when clinical suspicion is suggestive for the possibility of malignancy (Table 4).
### Table 3. Diagnostic Performance of Endoscopic Ultrasound and Computerized Tomography for Solid Pancreatic Cancers

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>EUS</th>
<th>EUS-FNA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sensitivity</strong></td>
<td>63-84%</td>
<td>95-100%</td>
<td>79-95%</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>35-93%</td>
<td>19-81%</td>
<td>69-100%</td>
</tr>
<tr>
<td><strong>Negative Predictive Value</strong></td>
<td>12-49%</td>
<td>48-100%</td>
<td>31-78%</td>
</tr>
<tr>
<td><strong>Positive Predictive Value</strong></td>
<td>89-99%</td>
<td>85-98%</td>
<td>94-100%</td>
</tr>
<tr>
<td><strong>Accuracy</strong></td>
<td>70-88%</td>
<td>97-98%</td>
<td>81-96%</td>
</tr>
</tbody>
</table>

### Table 4. Diagnostic Performance of Endoscopic Ultrasound with and without Fine Needle Aspiration in Comparison to Computerized Tomography for Pancreatic Cancers in the Presence and Absence of Obstructive Jaundice

<table>
<thead>
<tr>
<th></th>
<th>CT</th>
<th>EUS</th>
<th>EUS-FNA</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>General Performance</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sensitivity</strong></td>
<td>51-80%</td>
<td>92-100%</td>
<td>71-94%</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>16-100%</td>
<td>1-99%</td>
<td>16-100%</td>
</tr>
<tr>
<td><strong>Negative Predictive Value</strong></td>
<td>1-36%</td>
<td>25-100%</td>
<td>3-60%</td>
</tr>
<tr>
<td><strong>Positive Predictive Value</strong></td>
<td>88-100%</td>
<td>88-100%</td>
<td>91-100%</td>
</tr>
<tr>
<td><strong>Accuracy</strong></td>
<td>53-81%</td>
<td>89-100%</td>
<td>72-94%</td>
</tr>
<tr>
<td><strong>Obstructive Jaundice</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Sensitivity</strong></td>
<td>70-98%</td>
<td>87-100%</td>
<td>80-100%</td>
</tr>
<tr>
<td><strong>Specificity</strong></td>
<td>24-91%</td>
<td>16-84%</td>
<td>63-100%</td>
</tr>
<tr>
<td><strong>Negative Predictive Value</strong></td>
<td>24-91%</td>
<td>40-100%</td>
<td>52-100%</td>
</tr>
<tr>
<td><strong>Positive Predictive Value</strong></td>
<td>70-98%</td>
<td>69-96%</td>
<td>86-100%</td>
</tr>
<tr>
<td><strong>Accuracy</strong></td>
<td>65-93%</td>
<td>73-97%</td>
<td>85-100%</td>
</tr>
</tbody>
</table>

#### 5.1 Cancer staging

The accuracy of EUS for the stage of patients with pancreatic cancer is superior to US and CT scans with values ranging between 85 and 100% in comparison to 64-66% for CT and 61-64% for US. The EUS accuracy in staging pancreatic cancer does not depend on the use of radial or linear scanners. Initial studies showed excellent accuracy up to 94%, but later publication reported lower values ranging between 63% and 78%. Overall, EUS-FNA is highly sensitive (84%), specific (97%), accurate (84%) and has a high positive predictive value (99%), but relatively low negative predictive value (64%) (Table 5). A major problem in staging pancreatic cancer is the prediction of resectability as the best chance for long-term survival occurs in patients with localized disease undergoing resection. The primary goal of surgical therapy is to achieve a margin-negative R0 resection with minimal postoperative complications and a secondary important goal is to avoid unnecessary laparotomies for unresectable tumors.
Combining the pre-operative utilization of CT and EUS proved to be the method with the highest accuracy compared to each single technique to predict tumor resectability. In this context, a preoperative assessment of R0 resectability becomes critically important. Radiologic staging with EUS and CT or MRI is currently used to identify patients who may be resectable. The criteria of unresectability of pancreatic cancer include evidence of distant metastasis, tumor encroachment (defined as tumor surrounding the vessel more than 180 degrees) of arteries such as the celiac artery, hepatic artery, superior mesenteric artery (SMA) or massive venous invasion with thrombosis. Portal or superior mesenteric venous invasion without thrombosis or obliteration of vessels can still be classified as resectable tumors. A recent study comparing the roles of EUS, CT, MRI and angiography in the assessment of pancreatic cancer staging and resectability, has shown that CT scan was the most accurate in assessing the stage of the tumor (73%), locoregional invasion (74%), vascular involvement (83%), distant metastases (88%), final TNM stage (46%) and overall tumor resectability (83%). Although EUS appeared to be superior to detect smaller tumors not visualized by CT scan it is important to recognize that most surgeons would probably not rely on EUS alone before making important therapeutic decisions about surgical resections.

<table>
<thead>
<tr>
<th></th>
<th>No Discrete Mass on CT</th>
<th>Discrete Mass on CT Scan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sensitivity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS</td>
<td>82-100%</td>
<td>93-100%</td>
</tr>
<tr>
<td>EUS-FNA</td>
<td>65-99%</td>
<td>77-96%</td>
</tr>
<tr>
<td>Specificity</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS</td>
<td>29-96%</td>
<td>0-71%</td>
</tr>
<tr>
<td>EUS-FNA</td>
<td>59-100%</td>
<td>29-100%</td>
</tr>
<tr>
<td>Negative Predictive Value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS</td>
<td>48-100%</td>
<td>na</td>
</tr>
<tr>
<td>EUS-FNA</td>
<td>40-97%</td>
<td>7-70%</td>
</tr>
<tr>
<td>Positive Predictive Value</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS</td>
<td>68-99%</td>
<td>85-99%</td>
</tr>
<tr>
<td>EUS-FNA</td>
<td>79-100%</td>
<td>92-100%</td>
</tr>
<tr>
<td>Accuracy</td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS</td>
<td>63-99%</td>
<td>85-99%</td>
</tr>
<tr>
<td>EUS-FNA</td>
<td>74-99%</td>
<td>78-96%</td>
</tr>
</tbody>
</table>

Table 5. Diagnostic Value of Performing EUS-FNA Along with Spiral CT in Patients with Suspected Pancreatic Cancer

5.2 Conclusions
EUS-FNA has greatly impacted the diagnostic management of patients affected by pancreatic masses in conjunction with other cross sectional imaging tests. EUS is the best
method for tissue diagnosis and it is extremely useful for the management of patients who are not surgical candidates and who require neo-adjuvant or palliative chemoradiation therapy. Conversely, pre-operative tissue diagnosis is not indispensable for resectable tumors and therefore EUS plays a lesser role in this group of patients. In recent years, EUS has assumed an important interventional role in the management of patients who are affected by debilitating pancreatic cancer pain as it is extremely useful in obtaining celiac plexus block for long term analgesic effects. Current role of EUS and EUS-FNA is summarized in Figure 1.

6. Pancreatic cystic lesions

Pancreatic cystic lesions (PCLs) are commonly identified due to increased use of cross-sectional imaging in patients with non-specific abdominal complaints. Although their exact prevalence is unknown, it is estimated to range from 1% to 2.6% of the general population based on large scale observational imaging studies using MDCT81,82. Pancreatic cystic lesions are strongly associated with increasing age and Asian race82. Their relative frequency varies substantially geographically and by institution (primary vs. secondary) due to different practices and patient populations 83. In addition, the prevalence of PCLs including intraductal papillary mucinous neoplasms (IPMNs) was found to be higher among patients on hemodialysis compared to the normal population 84.

Inflammatory pseudocysts represent about 75% of pancreatic cysts; however they are not classified as true PCLs since they are non-epithelial inflammatory fluid collections associated with acute or chronic pancreatitis 85. Based on surgical pathology, PCLs are classified according to the characteristics of the cells lining the cyst in benign, premalignant and malignant 86(Table 6).

Serous cystadenomas (SCAs), mucinous cystadenocarcinomas (MCAs) and IPMNs represent 90% of PCLs and only the mucin producing neoplasms have been described to have risk of malignancy 87. In a small percentage of patients, solid malignant tumors such as adenocarcinoma, neuroendocrine tumors and other less common causes can present with cystic degeneration 88.

6.1 Limitations of radiological imaging modalities for the diagnosis of PCLs

Trans-abdominal ultrasound (US) is a safe and cheap diagnostic modality that can be used to diagnose PCLs, however, its sensitivity and specificity are often affected by the operator’s experience and the technical characteristics of the machine 89. In addition, the deep position of the pancreas and the interposition of other organs such as the stomach and the transverse colon limit the capacity of US to identify small PCLs. The overall sensitivity of US in detecting pancreatic lesions ranges from 48% 8 to 89% 20.

The majority of studies describing the role of CT and MRI in the diagnosis of PCLs have been small and retrospective. Relying on radiological characteristics alone can be misleading, with up to 40% of serous and mucinous lesions being misdiagnosed as pseudocysts 85,90. Reported overall diagnostic accuracy for these lesions has been highly variable ranging between 20% and 83% 91-93. (Table 7)

In a large group of patients, accurate preoperative diagnosis of PCLs was reported in 20% for serous cystadenoma, 30% for mucinous cystadenoma and 29% for mucinous cystadenocarcinoma, as the majority of these lesions were misdiagnosed as pseudocysts 92. MRI is equal or slightly superior to CT in diagnosing PCLs except in its limited ability to demonstrate calcifications in the tumor wall or septa 94.
**Pseudocysts (no epithelial lining)**
- Conventional pseudocysts
- Paraduodenal wall cyst (cystic dystrophy)
- Infection-related pseudocysts

**Cysts with mucinous epithelium**
- Intraductal papillary mucinous neoplasms
- Intraductal oncocytic papillary neoplasms
- Mucinous cystic adenoma
- Mucinous cystic adenocarcinoma
- Mucocele
- Retention cysts

**Serous (clear-cell) cystic tumors**
- Serous cystadenoma
- VHL-associated pancreatic cysts
- Serous cystadenocarcinomas (Extremely rare, case reports)

**Squamous-lined cysts**
- Lymphoepithelial cysts
- Epidermoid cysts within intrapancreatic accessory spleen
- Dermoid cysts
- Squamoid cyst of pancreatic ducts

**Cysts lined by acinar cells**
- Acinar cell cystadenocarcinomas
- Acinar cell cystadenomas (cystic acinar transformation)

**Endothelial-lined cysts**
- Lymphangiomas

**Degenerative or necrotic changes in solid tumors**
- Solid-pseudopapillary tumor
- Cystic change in ordinary ductal adenocarcinoma
- Cystic pancreatic endocrine neoplasia (islet cell tumors)
- Cystic mesenchymal neoplasms

**Other rare cystic lesions**
- Cystic hamartomas
- Endometriotic cyst
- Metastatic cystic neoplasms
- Congenital or developmental cysts
- Others

VHL = Von Hippel-Lindau

Table 6. Pancreatic cystic lesions classified by cells lining the cavity
For IPMN, magnetic resonance cholangiopancreatography (MRCP) seems to be superior to endoscopic retrograde cholangiopancreatography (ERCP) in detecting cysts communicating with the main pancreatic duct.  

6.2 Endoscopic ultrasonography
Endoscopic ultrasound (EUS) allows high resolution imaging of the pancreas with the ability to provide fine morphological details. The combination of fine-needle aspiration (FNA) cytology with the other recently available diagnostic markers has further increased its diagnostic accuracy. Indications for EUS-FNA should be considered based on diagnostic accuracy of alternative modalities, costs, patient comfort and safety and should be performed only when the information obtained has the potential to alter patient’s management. EUS-FNA should not be performed when there is inability to clearly visualize the target lesion, presence of large vessels interposed in the path between the needle and the lesion, bleeding diathesis and for patients at high risk of tumor seeding such as those with cholangiocarcinoma who are considered for liver transplantation. Once a cystic lesion is identified, the main clinical issue is the characterization and eventual therapeutic approach. Diagnostic accuracy of EUS imaging alone for differentiating malignant versus premalignant or benign lesions is ranging between 82% and 96%. The endosonographic features suggestive of malignancy are: wall thickness of 3 mm or greater, macroseptations with cystic compartments greater than 10 mm, presence of a mass or intramural growth or cystic dilation of the main pancreatic duct. These features have a sensitivity of 91%, a specificity of 60% and an accuracy of 72% in predicting malignant or potentially malignant PCLs. The sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV) and accuracy of EUS in comparison to other imaging modalities is summarized in Table 7. Despite EUS alone is a very sensitive test, EUS-guided fine needle aspiration (FNA) provides additional information for the characterization of PCLs. In a study by Frossard et al., the results of EUS and EUS guided FNA were compared with the final surgical pathology report. The sensitivity, specificity, PPV and NPV of EUS-guided FNA in this study were 97%, 100%, 100% and 95% respectively. On the other hand, corresponding values for EUS imaging alone were 71%, 30%, 49% and 40% respectively. Yet, the overall sensitivity and accuracy of EUS-FNA cytology remains widely variable with average sensitivity and accuracy around 50%.  

6.3 Cytology
The aspirated cyst fluid is generally analyzed for tumor markers, chemical and molecular analysis. Solid component associated with PCLs or regional lymph nodes can be aspirated for cytology or histology. EUS guided FNA is safe and rare complications include pancreatitis (2-3%), intracystic hemorrhage (<1%) and infection (<1%). The administration of antibiotic during the procedure is a common practice even if there are no data to support it. Tumor cell seeding has been a significant concern; there is limited evidence on the actual rise of tumor spread by EUS-FNA. Recent study has shown that EUS-FNA has a decreased risk of peritoneal tumor spread as compared with computed tomography-guided FNA (2.2% vs. 16.3%) . During EUS-FNA, the operator should always avoid to insert the needle through malignant tissue to reach a suspicious lesion. An example of this may be a patient with gastric or esophageal cancer and a suspicious lymph node adjacent to the primary tumor as the needle would have tumor entrapped into the channel that could contaminate the final results.
<table>
<thead>
<tr>
<th>Diagnostic modality</th>
<th>Author</th>
<th>Year</th>
<th>Sensitivity (%)</th>
<th>Specificity (%)</th>
<th>PPV (%)</th>
<th>NPV (%)</th>
<th>Accuracy (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>Giovanni et al⁸</td>
<td>1994</td>
<td>48-95</td>
<td>40-91</td>
<td>92</td>
<td>100</td>
<td>46-64</td>
</tr>
<tr>
<td></td>
<td>Bottger et al¹⁰</td>
<td>1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Rosch et al⁵</td>
<td>1991</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Niederau et al¹⁰⁵</td>
<td>1992</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Palazzo et al²¹</td>
<td>1993</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Tanaka et al¹⁰⁶</td>
<td>1996</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Doppler US</td>
<td>Candiani et al¹⁰⁷</td>
<td>1998</td>
<td>50-94</td>
<td>80-100</td>
<td>79</td>
<td>88</td>
<td>81-95</td>
</tr>
<tr>
<td></td>
<td>Casadei et al²³</td>
<td>1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>calculli et al¹⁰⁸</td>
<td>2002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>EUS</td>
<td>Akahoshi et al⁷²</td>
<td>1998</td>
<td>98</td>
<td>97</td>
<td>94</td>
<td>100</td>
<td>90</td>
</tr>
<tr>
<td></td>
<td>Sedlack et al¹⁰⁴</td>
<td>2002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Legmann et al⁵⁵</td>
<td>1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contrast enhanced US</td>
<td>Dietrich et al¹⁰³</td>
<td>2008</td>
<td>90</td>
<td>100</td>
<td>100</td>
<td>86</td>
<td>93</td>
</tr>
<tr>
<td>CT</td>
<td>Bronstein et al²⁶</td>
<td>2004</td>
<td>77</td>
<td>100</td>
<td>na</td>
<td>na</td>
<td>73</td>
</tr>
<tr>
<td></td>
<td>Megibow et al²⁷</td>
<td>1995</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MDCT</td>
<td>Park et al¹¹⁰</td>
<td>2009</td>
<td>83-91</td>
<td>63-75</td>
<td>80</td>
<td>87</td>
<td>85-95</td>
</tr>
<tr>
<td></td>
<td>Vargas et al³⁰</td>
<td>2004</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Diehl et al³¹</td>
<td>1998</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Schima et al³³</td>
<td>2002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MRI-MRCP</td>
<td>Anderssonet al³⁷</td>
<td>2005</td>
<td>83-92</td>
<td>63-85</td>
<td>95</td>
<td>79</td>
<td>89</td>
</tr>
<tr>
<td>PET</td>
<td>Maemura et al³⁸</td>
<td>2006</td>
<td>87-100</td>
<td>67-77</td>
<td>94</td>
<td>100</td>
<td>85-95</td>
</tr>
<tr>
<td></td>
<td>Delbeke et al¹¹¹</td>
<td>1999</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: Ultrasound (US), Endoscopic ultrasound (EUS), Computed tomography (CT), Multi detector computed tomography (MDCT), Positron emission tomography (PET)

Table 7. Summary of the performance characteristics of imaging tests for the diagnosis of pancreatic cancer

6.4 Cystic fluid markers

Several markers can be measured in the fluid aspirated from the pancreatic lesions during EUS to differentiate mucinous from non mucinous cysts. The most commonly used are; CEA, carbohydrate antigen (CA) 19-9, CA 72-4, and CA 15-3. CEA appears be the most useful as levels higher than 192 ng/ml had an accuracy of 79% for mucinous lesion characterization and was superior to cytology and EUS morphology.

Other markers such as amylase and lipase are important in the evaluation of cystic pancreatic lesions. Amylase is usually elevated in inflammatory cysts like pseudocysts but also in IPMN due to communication between the cystic lesion and the pancreatic duct. Amylase level less than 250 U/L favors the diagnosis of benign or malignant cystic neoplasms versus pancreatic pseudocysts (sensitivity 44%, specificity 98%).
Molecular markers are recently considered a more reliable alternative. A multicenter study on pancreatic cyst fluid DNA analysis demonstrated a strong association of mucinous cystic neoplasms with K-ras mutations occurring with other loss of heterozygosity (LOH) mutations\textsuperscript{118}. Shen et al\textsuperscript{119} assessed the correlation between this molecular diagnosis with a clinical consensus diagnosis for PCLs defined by histology, malignant cytology, or two concordant tests (such as EUS, cytology, or CEA>192 ng/ml for mucinous cysts). The study showed that the two diagnostic methods correlated well and molecular analysis of pancreatic cyst fluid added diagnostic value to the preoperative diagnosis.

7. Conclusion
Pancreatic cystic lesions are detected more frequently than in the past due to more sensitive imaging modalities. The differentiation between benign and malignant cystic lesions is often challenging. EUS and EUS-FNA have become a leading modality for the differential diagnosis of these lesions as it provides imaging characteristics and the possibility of obtaining cytology or fluid samples with high sensitivity and specificity. Characterization of cystic morphology by other imaging studies should be supplemented by EUS-FNA as cytology, tumor markers and DNA analysis can further characterize these lesions and increase the diagnostic accuracy of premalignant and malignant cysts.

8. Summary
Despite the advancement of other cross sectional imaging tests, EUS appears to have a higher sensitivity in detecting small pancreatic neoplasms in comparison to CT. On the other hand EUS does not appear to be accurate enough in assessing the invasion of SMA and SMV and respectability of locally advanced tumors. Recent studies have shown improved diagnostic performance of EUS with the use of parenteral contrast agents and EUS-FNA plays a key role when tissue diagnosis is needed.

9. References
\begin{itemize}
\end{itemize}


Surgeons from various domains have become fascinated by endoscopy with its very low complications rates, high diagnostic yields and the possibility to perform a large variety of therapeutic procedures. Therefore during the last 30 years, the number and diversity of surgical endoscopic procedures has advanced with many new methods for both diagnoses and treatment, and these achievements are presented in this book. Contributing to the development of endoscopic surgery from all over the world, this is a modern, educational, and engrossing publication precisely presenting the most recent development in the field. New technologies are described in detail and all aspects of both standard and advanced endoscopic maneuvers applied in gastroenterology, urogynecology, otorhinolaryngology, pediatrics and neurology are presented. The intended audience for this book includes surgeons from various specialities, radiologists, internists, and subspecialists.

How to reference
In order to correctly reference this scholarly work, feel free to copy and paste the following: